Volume 14, Number 11—November 2008
CME ACTIVITY - Research
Antimicrobial Drug Use and Resistance in Europe
Table 1
Substance class (ATC category) | Antimicrobial use, DIDs, 2004 |
Changes in antimicrobial drug use, 2000–2004 |
||||
---|---|---|---|---|---|---|
Maximum (country) | Minimum (country) | fd | >15% increase | >15% decrease | ||
Total use (J01) | 33.4(GR) | 9.7 (NL) | 3.4 | HU, DK, GR, IE | BG, CZ, DE, FR | |
Penicillins (J01C) | 12.8 (FR) | 3.4 (DE) | 3.8 | HU, DK | CZ, FR, DE, SK | |
Cephalosporins, monobactams, carbapenems (J01D) | 7.2 (GR) | 0.05 (NL) | >100 | SI | BE, BG, CZ, FR, IS NL, ES, SE | |
Macrolides, lincosamines, streptogramins (J01F) | 9.9 (GR) | 0.8 (BG) | 12.4 | BG, HR, GR, IE, NL | BE, FR, DE, LU, ES | |
Fluoroquinolones (J01MA) | 3.04 (PT) | 0.28 (DK) | 10.9 | AT, BG, CZ, DK, FI, DE, HU, IE, LU, UK | SI |
*DID, defined daily dose/1,000 inhabitants; ATC, Anatomic Therapeutic Chemical classification; fd, factor difference.
†Country designations: AT, Austria; BE, Belgium; BG, Bulgaria; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; LU, Luxembourg; NL, the Netherlands; PT, Portugal; SE, Sweden; SI, Slovenia; SK, Slovakia; UK, United Kingdom.
1National representatives of these 2 project groups in 2005 were as follows: Austria: H. Mittermayer, S. Metz, W. Koller (European Antimicrobial Resistance Surveillance System [EARSS]); Belgium: E. Hendrickx (EARSS), H. Goossens; Bulgaria: B. Markova; Croatia: A. Tambic-Andrasevic, Igor Francetic (European Surveillance of Antimicrobial Consumption [ESAC]), S. Kalenic (EARSS); Cyprus: D. Bagatzouni (EARSS); Czech Republic: P. Dvorak (ESAC), P. Urbaskova (EARSS); Denmark: D. Monnet, A. Anker Nielsen (ESAC); Estonia: P. Naaber (EARSS); Finland: P. Huovinen (ESAC), P. Paakkari (ESAC), O. Lyytikainen (EARSS), A. Nissinen (EARSS); France: P. Maugendre (ESAC), D. Guillemot (ESAC), B. Coignard, (EARSS), V. Jarlier (EARSS); Germany: W. Kern (ESAC), H. Schroeder (ESAC), W. Witte (EARSS), K. Heckenbach (EARSS); Greece: H. Giamarellou (ESAC), A. Antoniadou (ESAC), A. Tsakris (EARSS), A. Vatopoulos (EARSS); Hungary: G. Ternak (ESAC), M. Fuzi (EARSS); Iceland: K. Kristinsson; Ireland: E. Smyth (ESAC), R. Cunney (ESAC), D. Igoe (EARSS), O. Murphy (EARSS); Israel: R. Raz (EARSS); Italy: G. Cornaglia, A. Pantosti (EARSS), P. D’Ancona (EARSS); Latvia: S. Berzina (ESAC), A. Balode (EARSS); Lithuania: R. Valenteliene (ESAC), J. Miciulevicience; Luxembourg: R. Hemmer, M. Bruch (ESAC); Malta: M. Borg, P. Zarb (ESAC); the Netherlands: R. Janknegt (ESAC), M. Filius (ESAC), H. de Neeling (EARSS), E. Tiemermsa, J Degener (EARSS); Norway: H. Salvesen Blix (ESAC), A. Hoiby (EARSS), G. Simonsen (EARSS); Poland: W. Hryniewicz, P. Grzesiowski; Portugal: L. Caldeira (ESAC), M. Canica (EARSS); Romania: I. Codita; Slovakia: V. Foltan (ESAC), T. Tesar (ESAC), L. Langsadl (EARSS); Slovenia: M. Cizman (ESAC), M. Mueller-Premru (EARSS), J. Kolman (EARSS); Spain: J. Campos, F. Baquero (EARSS); Sweden: O. Cars (ESAC), G. Skoog (ESAC), B. Liljequist (EARSS), G. Kahlmeter (EARSS); Turkey: S. Unal (ESAC), D. Gür (EARSS); United Kingdom: P. Davey (ESAC), A. Johnson (EARSS), R. Hill (EARSS), H. Hughes (EARSS), M. Coyne (EARSS).